42 results about "CD24" patented technology

Disclosed are a CD24 antibody or an antigen-binding fragment thereof and the medical use thereof. Further, disclosed are a chimeric antibody comprising CDRs of the CD24 antibody, a humanized antibody, a pharmaceutical composition comprising the CD24 antibody or the antigen-binding fragment thereof, and the use thereof as an anticancer drug.

The invention discloses a diagnostic marker for ANCA (Angiovasculitis) related vasculitis. It is found for the first time that the CD19 + CD38 + CD27-CD24 + cell can be used as the diagnosis marker of ANCA related vasculitis, and the diagnosis efficiency is high; in addition, it is found that the CD19 + CD38 + CD27-CD24 + cells can remarkably distinguish ANCA related vasculitis and membranous nephropathy or ANCA related vasculitis and lupus nephritis, a new direction is provided for diagnosis and subsequent treatment of ANCA related vasculitis, and the application has wide application prospects clinically.

To provide a cell including a cell expressing CD24, and related method of use and creation thereof.SOLUTION: Provided is an isolated cell including modification for increasing reduced expression of MHC class I and / or MHC class II human leukocyte antigens and expression of CD24 in a cell. In some embodiments, the cell includes reduced expression of MHC class I and MHC class II human leukocyte antigens.SELECTED DRAWING: None

The invention discloses a bispecific antibody coupling drug targeting CD24 and HER2 and a preparation method and application thereof.The bispecific antibody coupling drug comprises an anti-CD24 heavy chain, an anti-CD24 light chain, an anti-HER2 heavy chain, an anti-HER2 light chain, a tetrapeptide linker and a topoisomerase I inhibitor exatan derivative, the DAR value of the bispecific antibody coupling drug is 9.25, and the anti-CD24 heavy chain, the anti-HER2 light chain, the tetrapeptide linker and the topoisomerase I inhibitor exatan derivative are different. The compound has strong cytotoxicity and internalization ability on breast cancer cells, not only can specifically target tumor tissues, but also can release drugs to kill target cells and adjacent tumor cells, and can significantly inhibit growth of breast cancer tumors. An antibody part DACH023 in the bispecific antibody coupling medicine is the same as a traditional IgG molecule, a traditional monoclonal antibody structure is reserved to the maximum extent, due to the existence of an Fc fragment, a common Protein A column affinity chromatography method can be adopted for purification, and large-scale production and purification are facilitated.

Provided are multispecific antibodies or fragments thereof having binding specificity to the human CD24 protein. Methods of using the antibodies or fragments thereof for treating cancer, autoimmune disease or inflammatory condition are also provided.

This invention provides a CD24-targeted nanomedicine delivery system and its application in the preparation of antitumor drugs. The nanomedicine delivery system of this invention comprises (1) a core structure: mesoporous manganese dioxide (hMnO₂) for co-loading glucose oxidase (GOx) and cysteine ​​(Cys); and (2) targeted delivery: nanoparticles encapsulated in a genetically engineered membrane EM-CD24 modified with the anti-CD24 single-chain variable fragment scFv. This invention can improve tumor penetration, reduce off-target accumulation, and enhance pharmacokinetics, achieving therapeutic Gox and cysteine ​​concentrations in the tumor while maintaining low systemic exposure, thus minimizing off-target toxicity.

The application discloses humanized anti-CD24 antibodies and application thereof, relates to the technical field of biological medicine, and specifically provides humanized antibodies capable of specifically recognizing CD24 and application thereof. FR regions and constant regions of a mouse-derived anti-CD24 monoclonal antibody are replaced by human-derived FR regions and constant regions, and CDR of the variable region of the mouse-derived anti-CD24 monoclonal antibody is retained, so that a series of anti-CD24 humanized monoclonal antibodies are obtained. The humanized antibodies obtained by the application have an affinity to CD24 antigens which is basically equivalent to that of a human-mouse chimeric anti-CD24 monoclonal antibody WT, and exhibit strong anti-tumor capacity in vivo.

The invention discloses an inflammatory bowel disease treatment method based on intestinal flora regulatory gene CD24 expression. According to the method, expression or functions of CD24 in host intestinal epithelial cells are up-regulated, the intestinal flora structure is adjusted, and intestinal inflammation is relieved. CD24 up-regulation can be realized by transfecting a CD24 gene overexpression vector, applying a transcription factor or a small molecule agonist or enhancing the activity of an endogenous gene by utilizing a gene editing technology. The CD24 is regulated and controlled, so that the proportion of the phylum firmicalis to the phylum bacteroides can be normalized, the enrichment of short-chain fatty acid producing flora is promoted, the activation of NF-kappa B and NLRP3 inflammasomes is inhibited, and the intestinal barrier function is enhanced. The DSS induced colitis model is established by drinking a 2-5% dextran sodium sulfate solution by a mouse, and simulates the pathological characteristics of human ulcerative colitis. Intervention modes include oral administration, enema or nanoparticle targeted delivery of the CD24 agonist pharmaceutical composition. The invention provides a new strategy for the treatment of inflammatory bowel diseases, especially ulcerative colitis, and has obvious dual curative effects of anti-inflammation and flora regulation.

Chimeric antigen receptors that bind to CD24, optionally further including CXCR3 or IL-15, and optionally further including EGFRt, polynucleotides encoding the receptors, cells comprising the polynucleotides, and methods of treating cancers using said chimeric antigen receptors or cells are disclosed.

GITRL+ IgDlow / − B cells as well as methods of making and using said cells are described herein. Also described are methods for treating an autoimmune disease or an inflammatory condition in a subject in need thereof of using said B cells. The B cells may be GITRL+ IgDlowCCR7+ CXCR5+ B cells or GITRL+ IgDlow CCR7+ CXCR5+ CD23+ CD24+ B cells.

The invention discloses a nerve cell differentiated from an immunoprivilege induced pluripotent stem cell and an application thereof. After main histocompatibility complex HLA-I and II type genes are inactivated in induced pluripotent stem cells, fusion protein XSG006 constructed by functional structural domains of CD47 and CD24 is over-expressed, the obtained induced pluripotent stem cells are differentiated to obtain separated low-immunogenicity dopaminergic neural precursor cells, and the low-immunogenicity dopaminergic neural precursor cells can be used for preparing the low-immunogenicity dopaminergic neural precursor cells on the basis of attack of escape T cells. And further, the NK cells and macrophages are escaped for killing. And attacks of an immune system can be effectively escaped in vivo. In a mouse Parkinson's disease model and a non-human primate (NHP) Parkinson's disease model, the strain can continuously survive in a host for a long time and generate activity, and the Parkinson's disease is fundamentally reversed. And an experimental basis and a theoretical basis are provided for establishing a PD treatment strategy and designing a novel stem cell treatment medicine.

The invention belongs to the field of biological medicine, and particularly discloses a culture method of domesticated mesenchymal stem cells (MSCs), which comprises the following steps: separating plasma and platelet lysis buffer from autologous peripheral blood, and obtaining CTL and Treg through magnetic bead sorting; the method comprises the following steps: sequentially co-culturing umbilical cord MSCs for three generations: co-culturing the P1 generation and CTL in a culture medium containing 30% of alpha MEM, 68% of DMEM / F12, 1% of autologous plasma and 1% of platelet lysis buffer, and adding 0.1-1 [mu] M of resveratrol and 10-50 [mu] M of spermidine; co-culturing P2 and Treg in a culture medium containing 50% of alpha MEM, 48% of DMEM / F12, 1% of autologous plasma and 1% of platelet lysis buffer; the P3 generation is cultured and harvested in 90% of alpha MEM, 5% of DMEM / F12 and 5% of PRP. The obtained MSCs surface marker is CD105 < + > / CD90 < + > / CD73 < + > / CD45 <-> / CD34 <-> / HLA-DR <->, the expression quantity of CD24 is low (CD24low), the expression quantity of CD47 is high (CD47high), the expression quantity of PD-L1 is high (PD-L1 high), the IDO activity is larger than or equal to 25 U / mg, the retention rate of the lung after vein transplantation is smaller than or equal to 12%, and the survival period is larger than or equal to 28 days. The cell is suitable for treating ARDS or hepatic fibrosis.

This invention relates to compounds, compositions and methods for treating, reversing or preventing cancer through the modulation of immune responses via Killer-specific Secretory Protein 37 (Ksp37). By enhancing immune recognition, Ksp37 downregulates the checkpoint proteins CD47 and CD24 on abnormal cells, allowing the immune system to effectively identify and eliminate cancerous cells. Additionally, Ksp37 influences cytokine signalling by increasing IL-12 and decreasing IL-2 levels, which supports the activation of natural killer (NK) cells while mitigating chronic inflammation, fostering an immune environment conducive to clearing abnormal cells.

The present disclosure relates generally to immunoglobulin-related compositions (e.g., antibodies or antigen binding fragments thereof) that can bind to the CD24 protein. The antibodies of the present technology are useful in methods for detecting and treating a CD24-associated cancer in a subject in need thereof.

A group of CD24-binding proteins and their uses are provided. Specifically, a group of antigen-binding proteins is provided in which cells expressing the antigen-binding protein may have cytotoxicity and safety. The use of antigen-binding proteins in the preparation of pharmaceuticals is also provided.

This invention relates to the application of targeting the ABHD17C-BCL6B-CD24 signaling axis in the preparation of pancreatic cancer treatment products, the products comprising diagnostic reagents and targeted drugs. The diagnostic reagent kit contains at least one of the following: a reagent for detecting ABHD17C, a reagent for detecting BCL6B expression, and a reagent for detecting CD24 expression. The targeted drug for improving the efficacy and prognosis of pancreatic cancer treatment contains at least one of the following: a reagent for inhibiting ABHD17C expression, a reagent for inhibiting BCL6B expression, and a reagent for inhibiting CD24 expression. This invention reveals the mechanism by which the ABHD17C-BCL6B-CD24 signaling axis regulates pancreatic cancer, providing a theoretical basis for the precise diagnosis and targeted therapy of pancreatic cancer, and has broad clinical application prospects.

Provided herein are antibody-drug conjugates containing an anti-CD24 antibody conjugated to a cytotoxic agent via a linker, in which the antibody selectively binds to human CD24 protein expressed on cancer cells but not human CD24 expressed in non-cancerous cells; and uses thereof for treating cancer.

The present specification describes CD24 binding antibodies and their fragments.The antibodies described herein have the useful property of not binding to either B cells or activated T cells.Such antibodies can have an enhanced safety profile with reduced immune side effects.In one aspect, the present specification describes an antibody or its antigen-binding fragment that binds to CD24, and the antibody does not bind to T lymphocytes.In certain embodiments, the antibody does not bind to activated T lymphocytes.

The invention discloses a 1q amplification type multiple myeloma marker as well as application and a detection preparation thereof. It is found for the first time that the CD19 + CD24-FCRL5 + cell subset content of a patient with multiple myeloma can be used as a marker for predicting and diagnosing 1q amplified multiple myeloma, and the cell subset can be used as a new target for the patient with 1q amplified multiple myeloma. According to the application disclosed by the invention, 1q amplification can be detected by a CD24-FCRL5 + subgroup existing in B cells of a patient with multiple myeloma, and the proportion of the cell subgroup is closely related to clinical detection of 1q amplification. The invention also discloses that the FCRL5 is inhibited to obviously inhibit the generation of malignant plasma cells, and the FCRL5 is of great significance to the treatment of clinical relapse and refractory 1q amplified MM patients.

The application discloses universal FASLG-expressing cells and a preparation method and application thereof. After major histocompatibility complex (MHC) class I and II genes are inactivated in cells and FASLG protein is overexpressed, the obtained human pluripotent stem cells or human cell lines or human induced pluripotent stem cells can further escape the killing of NK cells on the basis of escaping T cell attack, and the effect is even better than that of the reported star target CD47 and CD24. Meanwhile, the pluripotent stem cells with low immunogenicity retain stemness and differentiation ability.

Provided herein are antibodies or fragments thereof having binding specificity for human CD24 protein. In various examples, the antibodies or fragments thereof include VH and VL CDRs, or variants thereof, as disclosed herein. Also provided herein are methods of using the antibodies or fragments thereof to treat cancer.

The application discloses a VirusTAC platform for tumor cell membrane protein PD-L1 or CD24 targeted degradation and application thereof, and belongs to the technical field of biological medicine. The platform comprises a heterodimer with R1-R2-R3 structure formed by a first polypeptide chain and a second polypeptide chain, wherein R1 is MeV H or a variant thereof; R2 is a linker composed of R4 and R5, R4 is an IgG Fc region; R5 is a linker that can be cut by a protease; and R3 is a target protein binding domain PD-L1 antibody or CD24 antibody. The platform can specifically recognize tumor high-expression receptors and induce rapid endocytosis of cells by means of tumor-specific expression and efficient endocytosis characteristics of Nectin-4, so as to overcome the defects of the existing TPD technology and realize effective regulation of various target proteins.

The application provides an enzyme-responsive peptide-based nucleic acid targeting delivery system and a preparation method and application thereof, and relates to the technical field of biotechnology.The delivery system comprises nanomicelles and CD44-targeting nucleic acid aptamers connected to the outer layer of the nanomicelles; the nanomicelles are composed of enzyme-responsive peptides and CD24 siRNA adsorbed to the enzyme-responsive peptides; the enzyme-responsive peptide is a hydrophobic functional group-CGGFLG-HHHKKHHHKKK; and the CD24 siRNA targets and silences a CD24 gene.The delivery system can effectively target triple-negative breast cancer cells, and improves the targeting and drug loading capacity of a targeted drug for triple-negative breast cancer tumors.

The invention discloses an antigen epitope peptide coded by mRNA and fused in phosphatidylinositol anchoring protein and application of the antigen epitope peptide, and belongs to the field of biological medicine. The antigen epitope peptide comprises a MUC1 (1TR)-CD24 molecule and a MUC1 (1TR, 13aa)-CD24 molecule; the MUC1 (1TR)-CD24 molecule comprises an MUC1 signal peptide, an MUC1 extracellular domain containing one MUC1 VNTR sequence, a CD24 polypeptide and a phosphatidylinositol anchoring signal peptide; the MUC1 (1TR, 13aa)-CD24 molecule contains MUC1 signal peptide, MUC1 (1TR, 13aa) sequence, CD24 polypeptide and phosphatidylinositol anchoring signal peptide, the process is simple, the sequence is controllable, CAR-T cell amplification can be efficiently activated, CAR-T cells can be stimulated to secrete anti-tumor cell factors, and the MUC1 (1TR, 13aa)-CD24 molecule has important medical value in preparation of drugs for treating cancers or preventing cancer relapse.

The present invention relates to a novel anti-CD24 antibody and a use thereof, and more particularly, to a novel anti-CD24 antibody and a use thereof, the CD24-specific antibody according to one aspect can increase the phagocytic activity of macrophages in tumor tissues, can be used as a general anticancer agent to effectively prevent or treat various cancers related to CD24, is not limited to cancer species, has high binding affinity to both human and mouse, and can be used clinically and pre-clinically.

The application discloses an anti-CD24 antibody and application thereof. Specifically disclosed are an anti-CD24 antibody or an antigen binding fragment thereof, including a heavy chain variable region (SEQ ID NO: 1, 5, 9 or 13) and a light chain variable region (SEQ ID NO: 3, 7, 11 or 15). The anti-CD24 antibody (including a mouse-derived monoclonal antibody and three human-derived monoclonal antibodies) is obtained by a hybridoma technology and a CDR grafting method. The anti-CD24 antibody of the application has high affinity, can significantly inhibit the growth of tumors, and the tumor inhibition rate can reach 82.3%, has a significant anti-tumor effect, has a strong binding capacity with various tumor cells and tissues, does not bind with normal cells, and has good tumor selectivity. The antibody can be prepared into a prophylactic and therapeutic drug, a diagnostic drug and a detection kit for diseases related to a CD24 target point, and has a very wide clinical application prospect in the fields of tumor treatment and diagnosis.

Provided herein are anti-CD24 antibodies that selectively bind human CD24 expressed in cancer cells but not human CD24 expressed in non-cancerous cells, and glycan-shielded epitopes to which they bind. Also provided are uses of such antibodies and peptides in cancer therapy.

The present invention relates to a novel method for the diagnosis, prognosis, stratification and / or therapy monitoring of cancer diseases in patients. The method is based on the determination of CD3+ tumor infiltrating lymphocyte levels and CD24 expression. The novel biomarker combination of the present invention allows the diagnosis, prognosis, stratification and / or therapy monitoring of various cancer diseases. Furthermore, diagnostic kits for performing the non-invasive method of the present invention are provided.

A bispecific antigen binding protein, including (a) a first antibody or antigen binding fragment thereof that specifically binds to a first antigen; and (b) a second antibody or antigen binding fragment thereof that specifically binds to a second antigen. In the embodiments, the first antigen is CD24, and the second antigen is 4-1BB; or, the first antigen is 4-1BB, and the second antigen is CD24.

This invention discloses a shuttle peptide targeting YY1S247 phosphorylation and its application. The sequence of the shuttle peptide is shown in SEQ ID NO: 1. RQIKIWFQNRRMKWKK is a part of the Drosophila melanogaster tentacles peptide, used to provide cell penetration; PKKKRKV is the nuclear localization sequence of the SV40 large T antigen, used to guide the peptide into the cell nucleus; QIIGENSPPDYSE is the surrounding sequence of the YY1S247 site. The results show that the shuttle peptide (CPP) of this invention can competitively and specifically inhibit phosphorylation at the YY1S247 site, thereby inhibiting CD24 expression and enhancing the therapeutic effect of EGFR-TKIs.